Cancer BiologyLeukemiaPeer-reviewed
Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss
Samuli Eldfors, Sumit Rai, Vineet Sharma…·Timothy Aaron Graubert
This study identifies SRSF2 and U2AF1 mutations as biomarkers of sensitivity to ATR-CHK1 pathway inhibitors and RUNX1 mutations as a mechanism of resistance in MDS/AML.